The mTOR pathway in Gliomas: From molecular insights to targeted therapies

Safura Pournajaf1, Mohammad Hossein Pourgholami2

  • 1Hearing Disorders Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Insights

Glioblastoma multiforme (GBM) cells exploit the PI3K/AKT/mTOR pathway for aggressive growth and therapy evasion. Understanding this pathway

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Signaling

Background:

  • Glioblastoma multiforme (GBM) is an aggressive primary brain tumor with poor prognosis.
  • GBM cells manipulate intracellular signaling pathways, including PI3K/AKT/mTOR, for proliferation and invasion.

Purpose of the Study:

  • To provide a detailed review of the mTOR pathway's role in GBM.
  • To elucidate mTOR's modulators, upstream/downstream regulators, and interactions.

Main Methods:

  • Literature review of the PI3K/AKT/mTOR signaling pathway in GBM.
  • Analysis of mTOR's involvement in GBM cell biology and therapeutic resistance.

Main Results:

  • Molecular alterations in the PI3K/AKT/mTOR pathway are a hallmark of GBM.
  • This pathway drives GBM cell proliferation, angiogenesis, metastasis, and therapy escape.

Conclusions:

  • The PI3K/AKT/mTOR pathway is critical for GBM pathogenesis.
  • Understanding mTOR signaling is key for developing effective GBM therapies and overcoming resistance.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.0K